Switzerland-based global healthcare company Novartis (NVS) is gaining momentum this year, thanks to solid pipeline execution, new regulatory wins, high-value license transactions, capital return to shareholders, and positive market sentiment. Novartis stock has surged 36.3% year-to-date, outperforming the broader market.
Following Sandoz’s (SDZNY) 2023 spinoff, Novartis is a pure-play innovative medicines firm focused on high-value therapeutic areas.
